Everolimus - CISMeF

Preferred Label : Everolimus;

NCIt synonyms : 42-O-(2-Hydroxy)ethyl Rapamycin; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone;

NCIt related terms : RAD001; Afinitor;

NCIt definition : A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05);

Alternative definition : NCI-GLOSS: A drug used to treat advanced kidney cancer that did not respond to treatment with certain other anticancer drugs. It is also being studied in the treatment of other types of cancer. Afinitor stops cancer cells from dividing and may block the growth of new blood vessels that tumors need to grow. It also decreases the body's immune responses. It is a type of immunosuppressant and a type of antiangiogenesis agent.;

UNII : 9HW64Q8G6G;

InChIKey : HKVAMNSJSFKALM-GKUWKFKPSA-N;

CAS number : 159351-69-6;

Drug name : Certican; Afinitor; Zortress; Votubia;

Molecule name : RAD 001; RAD-001;

Chemical formula : C53H83NO14;

NSC code : 733504;

Codes from synonyms : CDR0000386203; CDR0000639748; CDR0000639749; 50567; 202;

Details

Origin ID

C48387;

UMLS CUI

C0541315;

CISMeF manual mappings
- Everolimus [MeSH Descriptor]
Currated CISMeF NLP mapping
- Everolimus [MeSH concept]
- Everolimus [ICD-11 Extension code]
- Everolimus [SMS substance]
- Everolimus [LOINC component]
- Everolimus (substance) [SNOMED CT concept]
- everolimus [Substance BNPC]
- everolimus [International Nonproprietary Name]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Everolimus [MeSH Descriptor]
- Everolimus [LOINC component]
- Everolimus (substance) [SNOMED CT concept]
- Product containing everolimus (medicinal product) [SNOMED CT concept]
- everolimus [ATC Code]
- everolimus [International Nonproprietary Name]
- everolimus [ATC Code]
Validated automatic mappings to BTNT
- everolimus [ATC Code]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Peptidyl-Prolyl Cis-Trans Isomerase FKBP1A [NCIt concept]
- Serine/Threonine-Protein Kinase mTOR [NCIt concept]
is_component_of_chemotherapy_regimen
- Bevacizumab/Everolimus Regimen [NCIt concept]
- Everolimus Regimen [NCIt concept]
- Everolimus/Exemestane Regimen [NCIt concept]
- Everolimus/Fulvestrant Regimen [NCIt concept]
- Everolimus/Gefitinib [NCIt concept]
- Everolimus/Imatinib Regimen [NCIt concept]
- Everolimus/Lenvatinib Regimen [NCIt concept]
- Everolimus/Letrozole Regimen [NCIt concept]
- Everolimus/Octreotide Long-acting Release Regimen [NCIt concept]
- Everolimus/Sorafenib Regimen [NCIt concept]
- Everolimus/Tamoxifen Regimen [NCIt concept]
- Gemcitabine/Cisplatin/Everolimus Regimen [NCIt concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients